{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a
to a specific field?
Status:
Investigational
Source:
NCT01839214: Phase 2 Interventional Completed Ulcerative Colitis
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
CI-201 (also known as VB-201) is pure synthetic Lecinoxoid, oxidized phospholipid analog, for prevention and treatment of atherosclerosis and central nervous system (CNS) autoimmune inflammatory disease. In preclinical models, CI-201 ameliorated the severity of experimental autoimmune encephalomyelitis (EAE) induced by myelin oligodendrocyte glycoprotein (MOG) peptide, and constrained the infiltration of pathogenic CD4+ T-cells into the CNS and impaired their IFN-γ production. CI-201 inhibits Toll-like receptor (TLR) signaling restricted to TLR-2 and TLR-4 in human monocytes and dendritic cells, and exhibits up to 90% inhibition of monocyte chemotaxis in vitro. Interestingly, CI-201 did not inhibit monocyte adhesion or phagocytosis and had no effect on chemotaxis of neutrophils. In vivo, oral treatment with CI-201 reduced monocyte migration in a peritonitis model and inhibited atheroma development in ApoE(-/-) mice, without affecting cholesterol or triglyceride levels. CI-201 is developed by Vascular Biogenics for the oral treatment of atherosclerosis, rheumatoid arthritis (RA), plaque psoriasis and multiple sclerosis (MS). However, in Phase 2 clinical trials CI-201 failed to demonstrate a statistically significant reduction in vascular inflammation associated with atherosclerotic lesions over placebo. As a result, Vascular Biogenics discontinued the development of CI-201 in psoriasis and atherosclerosis. No information about rheumatoid arthritis and multiple sclerosis clinical trials are currently available.
Status:
Investigational
Source:
NCT04573478: Phase 3 Interventional Active, not recruiting IgA Nephropathy
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Atrasentan (ABT-627, A-127722) is a selective endothelin A receptor antagonist. Atrasentan is being developed by AbbVie as an oral treatment for diabetic nephropathies.Abbott Laboratories was conducting clinical development of atrasentan for the treatment of certain cancers, including phase II trials for prostate cancer. However, no recent development has been reported for cancer indications and development is presumed to be discontinued.
Status:
Investigational
Source:
NCT00481455: Phase 2 Interventional Completed Recurrent Glioblastoma Multiforme
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
2-Methoxyestradiol (2ME2) is a natural metabolite of endogenous estrogen hormone 17β-estradiol in human and devoid of estrogenic activity. It is a drug that prevents the formation of new blood vessels that tumors need in order to grow (angiogenesis). It has undergone Phase 1 clinical trials against breast cancers. Preclinical models also suggest that 2ME2 could also be effective against inflammatory diseases such as rheumatoid arthritis. 2-Methoxyestradiol is an angiogenesis inhibitor, and has been shown to attack both tumor cells and their blood supply in preclinical testing. Presently, it is an investigational drug under various phases of clinical trials alone or in combination therapy. Its anticancer activity has been attributed to its antitubulin, antiangiogenic, pro-apoptotic and ROS induction properties. 2-Methoxyestradiol shows strong cytotoxic effect on estrogen dependent and independent cancerous cells, which is mainly due to disruption of microtubule process and p53 induced apoptosis through caspase, reactive oxygen species (ROS), superoxide dismutase (SOD) and nitric oxide synthase. 2-Methoxyestradiol inhibits tubulin polymerisation by binding to colchicine binding site of the tubulin and arrests cell cycle at G2/M-phase.
Status:
Investigational
Source:
NCT00277810: Phase 2/Phase 3 Interventional Completed Alzheimer Disease
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
LECOZOTAN, a benzodioxanylpiperazine derivative, is a selective serotonin 1A receptor antagonist. It was in development for the symptomatic treatment of cognitive deficits in Alzheimer's disease.
Status:
Investigational
Source:
NCT00421746: Phase 2 Interventional Completed Congestive Heart Failure
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Piboserod (SB 207266) is a selective 5-HT(4) receptor, antagonist. The 5-HT4 receptor antagonists are thought to antagonize both the ability of serotonin to sensitize the peristaltic reflex and 5-HT-induced defecation, at least in animal studies. As 5-HT4 receptors are present in human atrial cells and when stimulated may cause atrial arrhythmias, piboserod was under investigation in clinical trials for atrial fibrillation. In addition, GlaxoSmithKline studied the drug for the management of irritable bowel syndrome. Nevertheless, development both indications had been discontinued. Piboserod has successfully passed phase II clinical trials for the treatment of patients with congestive heart failure.
Status:
Investigational
Source:
NCT00082368: Phase 2 Interventional Completed Cancer
(2004)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Tariquidar, a non-competitive, specific P-glycoprotein (Pgp) inhibitor, is an anthranilamide derivative with multidrug resistance properties. Tariquidar binds to the ATP-binding cassette (ABC) transport protein Pgp, thereby inhibiting transmembrane transport of anticancer drugs resulting in their increased intracellular concentrations augmenting cytotoxicity of an anticancer drug. Tariquidar was discovered by Xenova Group and was developed for the treatment of multidrug resistance in cancer. In October 2002 the US Food
and Drug Administration (FDA) has granted fast track review status to tariquidar for the treatment of multi-drug resistance in first-line treatment of non-small cell lung cancer (NSCLC) patients. Tariquidar is still undergoing research as an adjuvant against multidrug resistance in cancer.
Class (Stereo):
CHEMICAL (RACEMIC)
Cintazone is a non-steroidal anti-inflammatory drug. It is was discovered in the 1960s, and was shown to be an anti-phlogistic agent in animal studies. Clinical development of this drug is not reported.
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
NCT03345095: Phase 3 Interventional Completed Newly Diagnosed Glioblastoma
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Marizomib is a natural beta-lactone produced by the marine bacterium Salinispora tropica. Marizomib has a broad inhibition profile for the 20S proteasome and has been shown to inhibit the CT-L (beta5) CT-T-laspase-like (C-L, beta1) and trypsin-like (T-L, beta2) activities of the 20S proteasome. The drug is being tested in phase II clinical trials for the treatment of Multiple Myeloma and Malignant Glioma and in phase I in patients with Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Class (Stereo):
CHEMICAL (RACEMIC)
Azabyperone was developed as tranquilizer and neuroleptic and has never been marketed.
